Clinical Trial Detail

NCT ID NCT02316340
Title Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors The University of Texas Health Science Center at San Antonio
Indications

colorectal cancer

Therapies

Vorinostat

Hydroxychloroquine

Regorafenib

Age Groups: adult

No variant requirements are available.